Nivolumab was found to upregulate CXCL9 in metastatic RCC [111], and a transcriptome study of >1000 patients found that CXCL9 was the second-most important predictor of response to ICIs in multiple tumor types, including RCC [76]. The gene discussed is CXCL9; the disease is neoplasm.